Pasar al contenido principal

INMUNOTERAPIA DE CANCER DE COLON MEDIANTE LA COMBINACION DE ANTICUERPOS BLOQUEANTES DE LA VIA INHIBIDORA PD-1-PD-L1 Y CELULAS DENDRITICAS AUTOLOGAS

PI17/00732

•
Nombre agencia financiadora Instituto de Salud Carlos III
Acrónimo agencia financiadora ISCIII
Programa Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de Investigación en Salud
Año convocatoria 2017
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACION PRIVADA CLINIC
Centro realización HOSPITAL CLINICO Y PROVINCIAL DE BARCELONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients, GEMCAD 1602 study

  • Español-Rego, Marta|||0000-0001-5497-2276
  • Fernández-Martos, Carlos
  • Elez, Elena|||0000-0002-4653-6324
  • Foguet, Carles
  • Pedrosa, Leire|||0000-0002-1852-4975
  • Rodríguez, Nuria
  • Ruiz-casado, Ana
  • Pineda, Estela|||0000-0003-2128-747X
  • Cid, Joan|||0000-0001-5445-4508
  • Cabezón, Raquel
  • Oliveres, Helena|||0000-0003-1801-1181
  • Lozano, Miquel|||0000-0003-2593-833X
  • Ginés, Angels
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Ayuso Colella, Juan Ramón|||0000-0002-5306-6850
  • Pagés, Mario
  • Cuatrecasas, Miriam|||0000-0003-3063-0110
  • Torres, Ferran|||0000-0002-7355-7913
  • Thomson, Timothy
  • Cascante, Marta
  • Benítez Ribas, Daniel|||0000-0002-2346-5324
  • Torres, Ferran|||0000-0002-7355-7913
Immune check-point blockade (ICB) has shown clinical benefit in mismatch repair-deficient/microsatellite instability high metastatic colorectal cancer (mCRC) but not in mismatch repair-proficient/microsatellite stable patients. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB as this combination has the potential to achieve synergistic effects. This was a Phase I/II multicentric study with translational sub-studies, to evaluate the safety, pharmacodynamics and anti-tumor effects of Avelumab plus ADC vaccine in heavily pre-treated MSS mCRC patients. Primary objective was to determine the maximum tolerated dose and the efficacy of the combination. The primary end-point was 40% progression-free survival at 6 months with a 2 Simon Stage. A total of 28 patients were screened and 19 pts were included. Combined therapy was safe and well tolerated. An interim analysis (Simon design first-stage) recommended early termination because only 2/19 (11%) patients were disease free at 6 months. Median PFS was 3.1 months [2.1-5.3 months] and overall survival was 12.2 months [3.2-23.2 months]. Stimulation of immune system was observed in vitro but not clinically. The evaluation of basal RNA-seq noted significant changes between pre and post-therapy liver biopsies related to lipid metabolism and transport, inflammation and oxidative stress pathways. The combination of Avelumab plus ADC vaccine is safe and well tolerated but exhibited modest clinical activity. Our study describes, for the first-time, a de novo post-therapy metabolic rewiring, that could represent novel immunotherapy-induced tumor vulnerabilities. The online version contains supplementary material available at 10.1007/s00262-022-03283-5.